CF-ARIA
Section 1

Understanding Cystic Fibrosis

At its core, cystic fibrosis is driven by a single issue: abnormally thick, sticky mucus. This underlying change explains the full scope of the condition, from the elevated salt levels in sweat to the vital importance of early detection.

What cystic fibrosis is

Cystic fibrosis is an inherited, lifelong condition caused by mutations in the CFTR gene. In a healthy body, this gene provides the instructions for a specialized protein channel embedded in the membranes of cells lining the lungs, digestive system, and sweat glands. This channel actively transports chloride (a component of salt) out of the cells, naturally drawing water toward the surface to keep mucosal layers hydrated, thin, and continuously moving.23

In people with cystic fibrosis, these channels are either defective, improperly shaped, or missing entirely. As a result, water remains trapped inside the cells, causing the protective fluid layer to dry out. This single physical shift turns normally slick, protective mucus into a thick, sticky buildup that clogs airways, traps bacteria, and hinders organ function across the body.29

CF is not contagious

You cannot catch cystic fibrosis. It is inherited, and it is present from birth, even when symptoms take years to become obvious. What can pass between people with CF are the bacteria that colonize CF airways, which is why CF centers take infection control between patients so seriously.12

Clinical detail: CFTR mutation classes

More than 2,000 CFTR variants have been catalogued, though only a subset are established as disease-causing. They are conventionally grouped by the mechanism of failure. The Cystic Fibrosis Foundation describes five classes;4 an expanded six-class scheme adds a sixth, for protein that is unstable once in place:5

  • Class I: no protein produced (nonsense, frameshift; e.g. G542X)
  • Class II: protein produced but misfolded and degraded before reaching the cell surface (F508del, by far the most common variant worldwide)
  • Class III: protein reaches the surface but the gate does not open (G551D)
  • Class IV: channel opens but conducts poorly (R117H)
  • Class V: reduced quantity of otherwise normal protein
  • Class VI: normal protein with an unstable surface half-life

Class matters clinically because CFTR modulator therapies act on specific defects: potentiators (ivacaftor) hold the gate open in class III/IV variants, while correctors (lumacaftor, tezacaftor, elexacaftor) improve trafficking in class II. Eligibility is genotype-dependent, which is one reason mutation spectrum varies so much in importance between populations4 (see Regional Resources).

How CF is inherited

Every person inherits two copies of the CFTR gene, taking one copy from each biological parent. Cystic fibrosis follows an autosomal recessive pattern of inheritance, meaning the condition only develops when a child inherits a mutated copy from both parents.2

Individuals who carry just one mutated gene alongside a healthy, working copy are known as carriers. Because that single functional gene produces enough protein to keep the body's salt and water channels working properly, carriers experience no symptoms and typically have no idea they carry the mutation. It is only when two carriers have a child together that the condition can be passed on, with a twenty-five percent chance in each pregnancy that the child will inherit both affected copies and develop cystic fibrosis.2

Inheritance pattern when both parents are carriers Two carrier parents, each with one working and one affected copy of the CFTR gene. Each pregnancy has a 25 percent chance of a child with no affected copy, a 50 percent chance of a carrier child with one affected copy, and a 25 percent chance of a child with cystic fibrosis carrying two affected copies. Parent (carrier) one working · one affected Parent (carrier) one working · one affected each pregnancy, independently Not affected not a carrier 25% Carrier healthy, no CF 25% Carrier healthy, no CF 25% Has CF two affected copies 25% working copy affected copy (carrier) affected copy (CF)
Autosomal recessive inheritance. When both parents are carriers, each pregnancy carries a one-in-four chance of a child with CF, a one-in-two chance of a carrier, and a one-in-four chance of a child with two working copies. These odds reset with every pregnancy: having one child with CF does not make the next three children unaffected.2
Clinical detail: carrier frequency, diagnosis, and why populations differ

Carrier frequency varies substantially by ancestry. It is highest in populations of Northern European descent (on the order of 1 in 25) and considerably lower in East and South Asian populations: historically low enough that CF was long assumed to be absent there, which contributed to systematic under-diagnosis rather than genuine absence.213

Diagnosis typically follows one of three routes:

  • Newborn screening: immunoreactive trypsinogen (IRT) on a heel-prick sample, followed by genetic testing and/or sweat testing. Widely implemented in North America, Europe, and Australia; not yet routine in much of Asia.6
  • Sweat chloride testing: the diagnostic standard. Values ≥60 mmol/L support a CF diagnosis; 30–59 mmol/L is intermediate and requires further evaluation.78
  • Genetic testing: identification of two disease-causing CFTR variants. Standard commercial panels are weighted toward variants common in European populations, so a negative panel does not exclude CF in South or East Asian patients; extended sequencing may be required.13

The practical consequence: in India and China, CF is frequently misattributed to recurrent pneumonia, tuberculosis, protein-energy malnutrition, primary ciliary dyskinesia, or idiopathic bronchiectasis, and diagnosis is often delayed by years.13

Symptoms and causes

Because CFTR sits in many different tissues, CF is a whole-body condition rather than purely a lung disease. Severity varies widely from person to person, and not everyone has every symptom.

How the same underlying defect produces different symptoms in different organs1911
Where What happens What it looks like
Lungs & airways Thick mucus is not cleared; bacteria become established; repeated infection drives inflammation and scarring. Persistent cough with thick sputum, wheeze, breathlessness, recurrent chest infections, eventual bronchiectasis.
Sinuses Same clearance failure in the upper airway. Chronic congestion, sinusitis, nasal polyps.
Pancreas Thick secretions block the ducts that carry digestive enzymes to the intestine. Poor weight gain despite a good appetite, bulky greasy stools, vitamin deficiency, and later CF-related diabetes.
Intestines Dehydrated intestinal contents move sluggishly. Meconium ileus in newborns, constipation, distal intestinal obstruction.
Liver & gallbladder Thickened bile obstructs small bile ducts. In a minority, CF-related liver disease.
Sweat glands Salt is not reabsorbed from sweat as it reaches the skin. Unusually salty-tasting skin; risk of salt depletion in heat. This is the basis of the sweat test.
Reproductive tract Absence or blockage of the vas deferens in most males. Male infertility (fertility treatment is often still possible); reduced fertility in females.

Signs that often prompt a first diagnosis

  • A newborn whose bowel does not open in the first days of life (meconium ileus)
  • Skin that tastes salty when kissed
  • Poor growth or weight gain despite eating well
  • Frequent chest infections that keep coming back after treatment
  • A cough that never fully goes away14
  • Clubbing (broadening and rounding of the fingertips and nails)19

How CF affects the lungs

The airways are lined with specialized cells carrying millions of microscopic, hair-like structures called cilia. In a healthy lung, these cilia sit within a thin, watery layer of fluid and beat continuously in coordinated waves. This motion pushes a protective layer of mucus, along with any trapped dust, pollen, and bacteria, steadily upward toward the throat where it can be cleared from the body. This vital, automatic cleanup process is known as the mucociliary escalator, and it operates around the clock without any conscious effort.911

In cystic fibrosis, the essential watery layer beneath the mucus is severely depleted. As a result, the cilia become flattened, trapped, and unable to beat effectively. At the same time, the mucus sitting above them becomes far too thick and sticky for the cilia to move, even during moments when they manage to sweep forward. The natural escalator comes to a complete halt, leaving trapped bacteria and debris stagnant inside the lungs and creating a prime environment for persistent infections.11

Cross-section comparison of a healthy airway surface and a CF airway surface In a healthy airway, a deep watery layer lets cilia stand upright and beat freely, moving a thin mucus blanket out of the lung. In a CF airway, the watery layer is shallow, cilia are flattened and immobile, and a thick mucus layer sits trapped on the surface where bacteria multiply. Healthy airway mucus moves out Thin, mobile mucus blanket Deep watery layer: cilia have room Airway lining cells Airway in cystic fibrosis clearance stalls Thick, sticky, trapped mucus Bacteria multiplying in the mucus Shallow watery layer: cilia flattened
Airway hydration and mucus clearance. The depth of the watery layer on the airway surface is what decides whether mucus moves. This is the direct rationale for two pillars of CF care: rehydrating the airway surface (for example with inhaled hypertonic saline) and applying mechanical force to shift mucus that will not move on its own.

The infection cycle

Stalled mucus is warm, wet, and nutrient-rich, an excellent place for bacteria to live. Once they settle in, a self-reinforcing loop begins:1112

  1. Mucus builds up

    Thickened secretions are not cleared and accumulate in the smaller airways.

  2. Bacteria colonize it

    Organisms establish themselves in the stagnant mucus, often Staphylococcus aureus and Haemophilus influenzae early in life, then increasingly Pseudomonas aeruginosa. Many form biofilms, which are far harder to eradicate than free-floating bacteria.

  3. The immune system responds intensely

    Neutrophils flood the airway. They struggle to clear organisms embedded in thick mucus, and the enzymes they release to fight infection also damage airway tissue.

  4. Airways are damaged and widen

    Repeated inflammation scars and permanently dilates the airways (bronchiectasis). Widened, floppy airways clear mucus even less well than before, so the loop tightens.

Why this makes daily treatment non-negotiable

The loop above is driven by mucus that sits still. Everything that gets mucus moving (airway clearance, inhaled therapies, and physical exercise) interrupts it. Because the mucus reaccumulates continuously, the interruption has to be daily and lifelong; it is maintenance, not a course of treatment that finishes. This is also why catching CF early matters: the loop starts before symptoms are obvious, and every year of undiagnosed disease is a year of unopposed damage.10

Clinical detail: pathogens, biofilms, and cross-infection risk

The organisms that drive the loop above, and why early identification of CF changes what is achievable against them:12

  • Pseudomonas aeruginosa: the dominant chronic pathogen in CF. It survives readily in standing water and damp equipment, and forms mucoid biofilms once chronic. Early aggressive eradication (inhaled tobramycin or colistin) can clear first isolation; once chronic, eradication is rarely achievable and treatment becomes suppressive.
  • Burkholderia cepacia complex: less common but disproportionately serious. Associated with accelerated decline and "cepacia syndrome", intrinsically resistant to many antibiotics, and demonstrably transmissible person-to-person. It is the principal reason people with CF are advised not to gather in person, and why equipment sharing is absolutely contraindicated.
  • Non-tuberculous mycobacteria (especially M. abscessus): increasingly recognized, notoriously difficult to treat, and found in domestic water systems. Treatment often requires multi-drug regimens over twelve months or more, with substantial toxicity and uncertain success.
  • Aspergillus fumigatus: may colonize or drive allergic bronchopulmonary aspergillosis (ABPA), which is treated differently from bacterial infection and is easily missed without it being looked for.

Segregation policy in most CF centers now assumes any person with CF may be carrying an organism transmissible to another, regardless of known culture status.

Further visual aids

Image coming soon
Image coming soon

Next